News Releases Year: All News20182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States Summary Toggle June 14, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record Summary Toggle June 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering Summary Toggle June 5, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model Summary Toggle May 31, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study Summary Toggle May 30, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present at 2018 BIO International Convention Summary Toggle May 29, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split Summary Toggle May 24, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™ Summary Toggle April 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board Summary Toggle April 9, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™ Summary Toggle April 3, 2018 View News Release > Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
